Page 2 - Zydus Lifesciences

Zydus Lifesciences hits all time high on USFDA nod for drug worth $2 Bn

Zydus Lifesciences stock surged as much as 2.61 per cent, hitting its all time high at Rs 1,313.05 per share on the BSE in Friday's intraday deals

Zydus Life gains over 2% on securing nod from COFERRIS to market Mamitra

The uptick in the stock price came after the pharmaceutical company announced that it has secured an approval from COFEPRIS of Mexico to market Mamitra to treat various cancers.

Zydus Life stock price jumps 6% on USFDA nod for Valsartan tablets

The shares surged after the pharmaceutical major announced that it has secured final nod from United States Food and Drug Administration (USFDA) for Valsartan tablets.

Gland Pharma, Zydus Lifesciences secure USFDA approvals for key medications

Gland Pharma, a Hyderabad-based generic injectable-focused company, received tentative approval for Latanoprostene Bunod Ophthalmic Solution, 0.024 per cent

Zydus Life Vadodara facility gets OAI report from USFDA, stock falls 3%

The fall in the stock came after the company announced that it has secured an Official Action Indicated (OAI) report from the United States Food and Drug Administration (USFDA).

Stocks to watch, July 19: Infosys, RIL, Vi, LTTS, Tata Consumer, DRL, CEAT

At 6:36 AM, GIFT Nifty futures were up 19 points, trading at 24,828.50 levels, indicating a higher start for the day.

USFDA classifies inspection of Zydus unit as 'official action indicated'

Zydus Lifesciences on Thursday said the US health regulator has cautioned that its Gujarat-based injectables plant may be subject to regulatory actions. The company said it has received a report from the US Food and Drug Administration (USFDA) for the inspection conducted at its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat between April 15-23, 2024. The USFDA has determined that the inspection classification of this facility is Official Action Indicated (OAI), it added. According to FDA, OAI means "objectionable conditions were found and regulatory administrative sanctions by FDA are indicated" during the inspection. "The company will work closely with the agency to resolve the regulatory status of this facility expeditiously," the drug maker said. Shares of Zydus Lifesciences settled marginally up at Rs 1,185.30 apiece on the BSE.

Zydus announces licensing deal with Takeda for new GERD drug Vault

Vault works by inhibiting the production of stomach acid and is approved by the Drugs Controller General of India (DCGI) for the treatment of reflux esophagitis and other acid peptic disorders (APDs)

Zydus Lifesciences hits all time high on USFDA nod for multiple drugs

Shares of Zydus Lifesciences zoomed up to 1.93 per cent, hitting its all time high at Rs 1203.20 per share on the BSE in Thursday's intraday trade

Zydus Life gets USFDA approval to market heart failure treatment drug

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in adults. The approval by the US Food and Drug Administration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing. Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company added.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Buzzing stocks today, July 1: Auto, Tata Consumer, HDFC Life, NTPC, Pharma

Stocks to Watch, Monday, July 1, 2024: Shares of Bajaj Auto, Maruti Suzuki India, Tata Motors, M&M, among other automobile stocks will be in focus amid the announcement of June auto sales data

Zydus gets tentative nod from USFDA for blood pressure lowering drug

Zydus Lifesciences Ltd on Friday said it has received tentative approval from the US health regulator to market Azilsartan Medoxomil and Chlorthalidone tablets, which are indicated for the treatment of high blood pressure. The tentative approval by the US Food and Drug Administration (USFDA) is for Azilsartan Medoxomil and Chlorthalidone tablets of strengths 40 mg/12.5 mg and 40 mg/25 mg, Zydus Lifesciences said in a regulatory filing. Azilsartan and Chlorthalidone are diuretic combination products indicated for the treatment of high blood pressure to lower blood pressure, it added. The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ- II, India, the company said. Azilsartan Medoxomil and Chlorthalidone tablets had annual sales of USD 77.9 million in the US, Zydus Lifesciences said citing IQVIA MAT March 2024 data.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

Concor, Dixon: Trading strategies for stocks with high long buildup in F&O

F&O stock update for May expiry: Page Industries, Concor, Dixon, Metropolis, Crompton Greaves and Zydus Life have seen notable long buildup in recent days. Here's a short-term outlook on the stocks.

Zydus Lifesciences stock rallies 5%; hits record high on robust Q4 results

EBITDA margin for the quarter stood at 29.5 per cent, an improvement of 440 bps on a YoY basis.

Stocks to Watch, May 18: Vodafone Idea, ZEE, Delhivery, Sobha, Zydus Life

Stocks to Watch on Saturday, May 18, 2024: Vodafone Idea is directing capital expenditure towards enhancing its 4G service coverage, aiming to expand its subscriber base

Zydus Lifesciences Q4 results: Profit rises four-fold to Rs 1,179 crore

On a sequential basis, the company exhibited a 22.83 per cent increase in revenue, the PAT also rose by 53.57 per cent

Zydus Lifesciences Q4 results: Net profit sees 4-fold jump at Rs 1,182 cr

Indian generic drugmakers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world

Zydus, MSN partner to license, supply affordable cancer tablets in the US

MSN Lab will manufacture and supply Cabozantinib; Zydus will handle marketing, distribution and sales